The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved under Priority Review DARZALEX^® (daratumumab), in combination with lenalidomide and dexamethasone (Rd), for newly diagnosed patients with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The approval is based on results from the Phase 3 MAIA clinical study published in the New England Journal of Medicine, which showed the DARZALEX^®-Rd combination reduced the risk of disease progression or death by 44 per cent compared to treatment with Rd alone.

Read more…